Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity

Cancer Research

Volumn 72, Issue 18, 2012, Pages 4744-4752

  Leandro García, Luis J ^a   Leskelä, Susanna ^a   Inglada Pérez, Lucía ^a   Landa, Iñigo ^a   De Cubas, Aguirre A ^a   Maliszewska, Agnieszka ^a   Comino Méndez, Iñaki ^a   Letón, Rocío ^a   Gómez Graña, Álvaro ^a   Torres, Raúl ^b   Ramiŕez, Juan Carlos ^b   Alvárez, Sara ^a   Rivera, José ^c   Martińez, Constantino ^c   Lozano, María Luisa ^c   Cascón, Alberto ^a   Robledo, Mercedes ^a   Rodríguez Antona, Cristina ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA TUBULIN 6; GENOMIC DNA; ISOPROTEIN; MESSENGER RNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BINDING; DRUG SENSITIVITY; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC VARIABILITY; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LYMPHOMA; MICROTUBULE ASSEMBLY; MISSENSE MUTATION; MULTIPLE MYELOMA; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TUBB1 GENE;

ANTINEOPLASTIC AGENTS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MICROTUBULES; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TUBULIN;

EID: 84866355213     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2861     Document Type: Article

References (32)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
2. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009;35:255-61.
3. Escuin D, Burke PA, McMahon-Tobin G, Hembrough T, Wang Y, Alcaraz AA, et al. The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle 2009;8:3914-24.
4. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez- Jimenez E, Leton R, et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 2010;67:214-23.
5. Jaglin XH, Poirier K, Saillour Y, Buhler E, Tian G, Bahi-Buisson N, et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat Genet 2009;41:746-52.
6. Tischfield MA, Baris HN, Wu C, Rudolph G, Van Maldergem L, He W, et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell 2010;140:74-87.
7. Italiano JE Jr, Bergmeier W, Tiwari S, Falet H, Hartwig JH, Hoffmeister KM, et al. Mechanisms and implications of platelet discoid shape. Blood 2003;101:4789-96.
8. Schwer HD, Lecine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. Alineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol 2001;11:579-86.
9. Freson K, De Vos R, Wittevrongel C, Thys C, Defoor J, Vanhees L, et al. The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure. Blood 2005;106:2356-62.
10. Navarro-Nunez L, Lozano ML, Rivera J, Corral J, Roldan V, Gonzalez- Conejero R, et al. The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica 2007;92:513-8.
11. Kunishima S, Kobayashi R, Itoh TJ, Hamaguchi M, Saito H. Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood 2009;113:458-61.
12. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant betatubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
13. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001;61:5803-9.
14. Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 2003;10:597-607.
15. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9.
16. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003;22:3548-53.
17. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-75.
18. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
19. McCoy JP Jr. Handling, storage, and preparation of human blood cells. Curr Protoc Cytom 2001; Chapter 5: Unit 5 1.
20. Rodriguez-Antona C, Leskela S, Zajac M, Cuadros M, Alves J, Moneo MV, et al. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood 2007;110:3345-51.
21. Fernandez A, De Arriba F, Rivera J, Heras I, Vicente V, Lozano ML. Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies. Haematologica 2008;93:1436-8.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
23. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
24. Aksentijevich I, Flinn I. Chemotherapy and bone marrow reserve: lessons learned from autologous stem cell transplantation. Cancer Biother Radiopharm 2002;17:399-403.
25. Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998;22:859-63.
26. Drake M, Ranaghan L, Morris TC, Nolan L, Desai ZR, Irvine AE, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997;98:745-9.
27. Sullivan KF, Cleveland DW. Identi fi cation of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc Natl Acad Sci U S A 1986;83:4327-31.
28. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferredby tubulinmutations in human cancer cells. Proc Natl Acad Sci U S A 2000;97:2904-9.
29. Torin Huzil J, Luduena RF, Tuszynski J. Comparative modelling of human beta tubulin isotypes and implications for drug binding. Nanotechnology 2006;17:S90-S100.
30. Huzil JT, Chen K, Kurgan L, Tuszynski JA. The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform 2007;3:159-81.
31. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus lowdose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
32. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;11:6625-33.